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Abstract: Acne is a multifactorial and inflammatory disease of pilosebaceous follicles, which 
affects most adolescents. Recent epidemiological data revealed a difference in adults affected 
by this disease. Women have a high prevalence and incidence when compared with men, espe-
cially after 25 years of age. In contrast to what was initially thought, most of these patients do 
not present endocrinopathy capable of leading to the development of the lesions. When present, 
polycystic ovarian syndrome is the main cause. However, in these cases, acne is rarely the only 
dermatological manifestation; hirsutism and acanthosis nigricans are often present. The majority 
of the normoandrogenic acne patients present a history since adolescence, but in many cases the 
lesion distribution and intensity change with time. There is often a typical localization of the 
lesions in the lower third of the face and lateral region of the neck. Another interesting feature 
is related to the impact on quality of life (QoL), which is always intense. Often there are signs 
of depression, even when the lesions are mild. As most adult patients are women, in addition to 
the conventional options, there is also hormone treatment. Combined oral contraceptives and 
spironolactone are good options. Knowing more about the particularities in etiopathogenesis, 
impact on QoL, and specific treatment options is important to all dermatologists who face the 
challenge of treating acne in adults.
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Introduction
Acne is one of the most prevalent inflammatory skin diseases. Epidemiological data 
have disclosed that, on a global scale, it is the eighth most frequent disease, with 9.4% 
predominance, including both adults and adolescents of several ethnic groups.1 Acne 
vulgaris, or acne of the adolescent, has a peak incidence in 14- and 17-year-old girls 
and in 16- and 19-year-old boys.2 
Recent research has shown an increase in total adult female acne (AFA) cases. 
Although with no absolute consensus, the surveys analyzed 26- to 44-year-old 
women.3–5 Perkins et al published North American data showing that 12%–22% women 
suffer from acne in their adult life.6 Another study performed by French researchers 
concluded that acne persists in 41% of adult women; half of them reported dyschromias 
and presence of scars, 78% described worsening of lesions during their premenstrual 
period, and above 90% reported manipulating the lesions. The authors pointed out that 
only 22% of those patients sought medical assistance.7 Upon analyzing statistical data 
on dermatological consultations to treat acne, Yentzer et al observed that adult patients, 
mainly women, corresponded to 61.9% of the total attendances.8 A community-based 
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survey of >700 people, older than 25 years, also reported 
clinical facial acne, in 12% of women and 3% of men.9 In 
the study published by Goulden et al, besides the increased 
predominance in adult women, the presence of a clinical 
picture with more severe lesions was verified compared to 
that affecting men in the same age group.4
It is not yet clear if there is a real increase in incidence 
in that age group or if access to information on the disease 
and/or treatment causes that group to look for specialized 
medical care.10 In the majority of cases, acne is persistent, 
meaning that lesions start in adolescence and persist in adult 
life. Goulden et al, upon the assessment of 200 adult women 
with acne, reported that only 18.4% presented a clinical 
picture of late onset, that is, at over 25 years of age. In the 
same study, a familial history of AFA was detected in 50% 
of patients.9 Dumont-Wallon and Dréno found similar data 
in relation to the family history; that is, 53% patients had 
first-degree relatives with AFA history. They also reported 
that 20%–40% of cases had late onset.11
For some researchers, there was still a third subtype 
related to the moment of the onset of the lesions. In such 
cases, the patient presented acne in adolescence, followed 
by an interval without the disease, and then a return in adult 
life of lesions with some different morphological features, 
mainly related to the distribution along the face.12
In a study by Golden et al to determine the presence of 
hormonal alterations in acne patients, evidence of biochemi-
cal hyperandrogenism was found in only 37%.9 Ozdemir et 
al’s analysis of the presence of endocrinological diseases in 
patients with isolated acne showed that over 50% did not 
present clinical or biochemical evidence of hyperandrogen-
ism.13 Since there is no consensus about the inclusion criteria 
in studies on AFA, mainly with respect to whether the pres-
ence of acne is isolated or associated with other androgenic 
alterations, such as hirsutism, it remains controversial which 
hormonal alterations are the most frequent and which could 
be used as markers for the disease.14 However, there seems 
to be some agreement in that, for the group of patients 
presenting with late-onset acne (at over 25 years of age), 
it would be more important to investigate the presence of 
endocrinological diseases. Thus, such a division between 
persistent and late-onset acne would act as a factor for the 
dermatologist to ascertain whether it is necessary to request 
complementary examinations.
Etiopathogenesis 
The etiopathogenesis of acne is multifactorial, immune-
mediated, and androgen-triggered. These hormones increase 
the production of sebum and stimulate follicular hyperkera-
tinization resulting in microcomedo.15 The inner glandular 
layer starts presenting an increase in colonization by Propi-
onibacterium acnes, a Gram-positive bacteria responsible 
for the onset of the inflammatory process.16–18
New data have disclosed that the development of lesions 
is related to the activation of the innate immunity, and that 
this process can occur even before follicular hyperkerati-
nization.18–26 Histopathological and immunohistochemical 
investigations confirm that a lymphocytic infiltrate composed 
of memory and effector T-cells is the first finding at the begin-
ning of the disease.27,28 Jeremy et al showed the existence of 
a center-follicular inflammatory process before the develop-
ment of the microcomedo.20
P. acnes is connected to toll-like receptors (TLRs) present 
in the keratinocytes, sebocytes, and dendritic cells, triggering 
signalizing cascades that activate transcriptional factors such 
as nuclear factor kappa B and phosphokinases such as mito-
gen activators.29,30 Such activation in the monocytes results 
in the release of two interleukins (ILs), IL-12 and IL-8.19 
IL-12 is the major inflammatory cytokine responsible for 
the immune response against the invasion of Gram-positive 
bacteria.31 
Another function of the TLRs in acne vulgaris could be 
the promotion of antimicrobial peptide release. There is a 
higher production of the antimicrobial peptide β-defensin 2 
by epithelial cells in response to the stimulation with TLR2 
and TLR4 antagonists. Such peptides can also activate the 
cells. Once there is an increased regulation or upregulation, 
of the β-defensins 1 and 2 in acne vulgaris lesions compared 
to the controls, their involvement in the pathogenesis of the 
disease was suggested.21 Rocha et al’s study of AFA patients 
showed that the TLR2 expression in sebocytes was increased 
both in the perilesional area and in the lesions, with supe-
riority of the latter. In the same study, the author compared 
the expression of that receptor in skin biopsies from women 
without acne, revealing a low expression when compared 
with the perilesional area of acne patients.32
IL-8, present in the follicular and surrounding regions of 
the acne lesions, is essential for the recruitment of neutro-
phils. These defense cells release lysosomal enzymes that 
result in the rupture of the follicular epithelium, worsening 
in the inflammatory process.31
P. acnes is also able to release several exogenous lipases 
and proteases that connect to the protease-activated recep-
tor 2 (PAR-2) present in the keratinocytes. The activation 
of the receptor increases the transition of several inflamma-
tory cytokines, including IL-1α, IL-8, and tumor necrosis 
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factor-α. Matrix metalloproteinases and LL-37 are also 
produced, a cathelicidin that is the only antimicrobial peptide 
member known in humans. Therefore, at least through the 
TLR and PAR-2, P. acnes is able to trigger the inflammatory 
process.19,33 
Studying cells obtained from inflammatory lesions in 
eight patients with acne, Tenaud et al verified an increase in 
the TLR2 expression when compared with the controls. By 
performing only an in vitro analysis, the researchers also 
proved that adapalene in two different concentrations, 10−7 
and 10−6 M, succeeded in reducing the TLR2 expression in 
cultivated keratinocytes. As this topical retinoid modulated 
the innate immune system in the studied cells, the authors 
concluded that this is one of the possible mechanisms that 
would explain its anti-inflammatory action.34 By treating 
two groups of patients with AFA for 6 months (one group 
with a combined oral contraceptive [COC] and the other 
group with 15% azelaic acid gel), Rocha et al demonstrated 
through immunohistochemistry, a reduction in the TLR2 
receptor expression in sebocytes parallel to the reduction of 
clinical lesions.32
Although several studies have confirmed that the skin of 
patients with acne has a higher P. acnes density, no relation-
ship to the inflammation severity has been verified.35,36
From a hormonal point of view, androgens are necessary 
for sebaceous production, and they play a key role in acne 
development.37 Women with severe acne present higher lev-
els of dehydroepiandrosterone sulfate (DHEAS) than those 
with mild to moderate acne. Such alteration is specific; it 
is not found with regard to other androgens, such as tes-
tosterone (T).38,39 Earlier studies with a reduced number of 
participants found increased levels of free testosterone (FT) 
and dihydrotestosterone (DHT) in adult women with acne.40,41
It has been proved that there is an alteration of the sebum 
components in acne patients when compared with healthy 
individuals. Of all components changed, linoleic acid (LA), 
which is an essential fatty acid, is the most important because 
it protects the follicular epithelial wall. With the reduction of 
LA, the epithelium is harmed by the free fatty acids resulting 
from the hydrolysis of triglycerides through lipases released 
by P. acnes. This mechanism results in infundibular hyper-
keratinization and dermal inflammation.26,42,43 
There is no acne development without the sebocytes’ 
proliferation and differentiation. Such processes are likely 
related to the correlation between androgens and peroxi-
some proliferator-activated receptors (PPARs), molecules 
that regulate lipogenesis along adipocyte differentiation. 
PPAR activation and hyperexpression can be required for 
lipogenesis that characterizes the final stage of sebocyte 
differentiation.44–46
Studies analyzing sebocyte cultures have shown that such 
cells are able to trigger an inflammatory process through an 
inherent mechanism by increasing the IL-1α expression.47 
IL-1α induces follicular hyperkeratinization, and it is present 
in high concentrations in the comedo.48
Hence, both IL-1α production by sebocytes and the 
production of free fatty acids with the ability to irritate the 
follicular epithelium can contribute as inherent factors to the 
evolution of acne inflammatory lesions.16 
Recent advances in the knowledge of mechanisms 
involved in triggering the acne inflammatory cascade have 
also proved the presence of a higher IL-17 expression in 
mononuclear cells present in the surrounding follicular 
infiltrate of the comedo, which seems to be induced by the 
presence of P. acnes. This fact leads to the conclusion that 
cellular response is not mediated only by T helper 1 lympho-
cytes but also by T helper 17 lymphocytes.49 
In adult women, a positive correlation was observed 
between DHT, DHEAS levels, and the inflammatory lesions 
severity, with blood levels of the insulin-like growth factor 1 
(IGF-1).40,50 Hyperinsulinemia influences both the IGF-1 
concentration in the blood and the insulin-like growth factor-
binding protein 3 (IGFBP-3) that acts directly in the keratino-
cytes’ proliferation and apoptosis. In a hyperinsulinemic state, 
the IGF-1 level rises and the IGFBP-3 decreases, thus causing 
a disbalance in keratinocyte hyperproliferation.51 IGF-1 seems 
to mediate comedogenic factors such as androgens, growth 
hormone, and glucocorticoids. A study in humans showed that 
the endogenous androgen increases IGF-1 serum levels and 
that IGF-1 increases androgen levels. Thus, a vicious circle is 
set, resulting in continuous sebum production.52,53
External hormonal factors are mainly connected to the use 
of pro-androgen progestins present in specific oral, injectable, 
or intrauterine device contraceptives, which may trigger or 
aggravate acne.4 
The use of cosmetics remains controversial. Several 
studies mention them as worsening factors,7,11,54 while others 
showed that the withdrawal of cosmetics did not contribute to 
the improvement of acne.10 Such differences can be explained 
by the existing diversity of cosmetics, mainly in relation to 
the vehicles and number of products. In a literature review 
about cosmetics and acne, Dall’oglio et al conclude that 
whenever well-indicated and of good quality, cosmetics help 
to improve the outcome of acne treatment; the researchers 
recommend the use of makeup to conceal the lesions, which 
results in higher adherence to the treatment.55
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For Goulden et al, the stress reported by 71% patients is 
a worsening factor for acne.9 Poli et al report that ~50% of 
women mentioned it as one of the worsening factors.7 The 
connection between stress and the worsening of acne is now 
understood through the higher production of neuromodula-
tors, such as the substance P, which connects to the recep-
tors also present in the sebaceous gland stimulating sebum 
production.10
In some recent studies, smoking habit was considered a 
factor associated with AFA persistence, which means that 
women who smoke present a higher frequency of the disease, 
resistance to treatment, and a higher amount of comedo.10,56,57 
Hormones and peripheral 
metabolism 
From the endocrinological point of view, a small percentage 
of women with AFA have hyperandrogenism. In those cases, 
the presence of other clinical alterations associated with acne 
is common, such as hirsutism, alopecia, change of voice 
timbre, irregularity of the menstrual cycle, and infertility. 
For those patients, the majority of authors suggest FT and 
TT, DHEAS, luteinizing hormone, follicular-stimulating 
hormone serum dosages, and transvaginal ultrasound of the 
ovaries. Such dosages must always be administered during the 
follicular phase, preferably between the first and fifth day of 
the menstrual cycle, and collection must be performed in the 
morning, between 8:00 and 10:00 am. This way, the hormonal 
variations of the menstrual cycle interfere less with the analy-
sis of the hormones.58,59 After such investigations, polycystic 
ovary syndrome (PCOS) is the more frequently associated 
cause diagnosed.60,61 Other rare endocrinological causes are 
virilizing tumors and congenital adrenal hyperplasia. 
Whenever there is a suspicion of PCOS, the following 
criteria must be checked:62 biochemical and clinical hyper-
androgenism abnormalities, the presence of ultrasound 
alterations, and amenorrhea or oligomenorrhea. According 
to the consensus revised in 2004, the presence of two of 
the three criteria confirm the diagnosis.62 It is important to 
point out that the most frequently reported dermatological 
manifestation in PCOS is hirsutism, present in 65%–73% 
of patients.63
The majority of patients with isolated AFA show no other 
signs of clinical hyperandrogenism and are therefore con-
sidered normoandrogenic.38,64 In contrast, some researchers 
found only a few high DHEAS levels, even in patients with 
acne nonrelated to hirsutism.39,65 Thiboutot et al analyzing a 
small sample (eight adult patients) detected an increase in the 
levels of DHEAS, androstenedione (A), FT, and DHT when 
compared with the control group. In this study, there was 
no description of the presence or absence of other clinical 
manifestations of hyperandrogenism.41
Although DHT can be considered a primary marker for 
the peripheral production of androgens, it is metabolized 
rapidly and has a high affinity for the sex hormone binding 
globulin.66 Conversely, when quantifying its distal metabolite, 
3α, 17β-androstanediol glucuronide (3α-diol), a better cor-
relation is attained with the androgens’ peripheral activity, 
mainly when related to the idiopathic cases of hirsutism.67 
Cappel et al analyzing the dosage of hormones related to the 
severity of acne verified an increase in the amount of DHT in 
women with persistent acne and a higher number of lesions.50
It remains unclear in the literature which are the possible 
abnormalities of the sebaceous gland’s functioning that would 
justify both the onset and the chronicity of the acne lesions. It 
is speculated that the androgens circulating at normal levels 
would act in an exaggerated way through a higher peripheral 
conversion and/or higher affinity for the receptors. One of 
the possibilities related to the peripheral conversion would be 
related to a higher activity of the type 1 steroid 5α-reductase 
responsible for the conversion of T into DHT.41
Androgenic production originates from the gonads, adre-
nal glands, and peripheral tissues, including the skin. The 
main blood sources of androgens in women are A, DHEAS, 
and T. DHEAS is produced by the adrenal glands, A by adre-
nals and ovaries, and T by the ovaries and peripheral tissues 
such as fat, muscle, and skin.59
As to the skin, especially the pilosebaceous unit can 
synthesize androgens directly from cholesterol68,69 or by the 
conversion of weak blood androgens into powerful andro-
gens (Figure 1). Similar to other steroid hormone producing 
organs, there are six enzymes responsible for this  metabolism: 
Figure 1 Pilosebaceous unit synthesis of androgens directly from cholesterol or by 
the conversion of weak blood androgens into powerful androgens.
Abbreviations: DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone.
Adrenal
Blood vessel
DHEA
DHT
ADT-G
3-diol-17G
Ovaries Peripheral tissues
Testosterone
Testosterone
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steroid sulfatase, 3β-hydroxysteroid dehydrogenase (3β-
HSD), 17β-HSD, 5α-reductase, 3α-HSD, and aromatase. 
Type 1 5α-reductase is mainly found in the sebaceous glands, 
while type 2 isoenzyme is located in the hair follicle.70 The 
conversion of weak androgens into powerful androgens 
begins with DHEA generating T and DHT. In the sebocytes 
particularly, steroid sulfatase, 3β-HSD1, 17β-HSD3, and 
type 1 5α-reductase are the main enzymes responsible for 
the production of the potent androgens, while 17β-HSD2, 
3α-HSD, and aromatase seem to locally deactivate exces-
sive androgen production, thus assuring homeostasis of that 
peripheral activity.71 Previous studies have proved that the 
levels of type 1 5α-reductase increased in the sebaceous 
glands in some regions prone to acne development.72,73 This 
way, the androgenic conversion in the skin is activated, and 
the androgens produced act directly on the intracellular recep-
tors, thus performing an intracrine function.74 
During the final phase of the metabolization process, 
the enzyme 3α-hydroxy-desidrogenase converts DHT into 
3α-androstenediol that suffers glucuronidation. Such modi-
fication decreases DHT’s affinity for the receptors, increases 
its hydrophilic property, and facilitates renal excretion.75 This 
metabolite can be used as a hyperandrogenism marker, mainly 
in women with idiopathic hirsutism.70 For cases of isolated 
acne, this marker did not show any effectiveness. On the other 
hand, earlier studies showed that ADT-G, another important 
androgenic metabolite, despite being assessed by techniques 
presently deemed less accurate, such as radioimmunoassay, 
presented a significant increase in patients with acne.64,76 
ADT-G corresponds to around 93% of the total androgen 
metabolites, and its serum dosage has already been used to 
quantify the total androgenic activity.73 
Ideally, measurement of the androgenic activity in 
peripheral tissues should be performed by quantifying the 
tissue concentration of the active androgens. However, this 
is usually impossible, except in sampling attained from spe-
cific types of cancer after surgical removal, as shown in the 
studies from the 1980s.77–79 Nevertheless, as it is not possible 
to access the androgenic activity in specific tissues, the use 
of more sensitive and specific laboratory techniques, such 
as liquid chromatography associated with mass spectrometry 
to dose a glucuronized derivate such as ADT-G, enables the 
assessment of the total androgenic activity in the body at a 
high accuracy level. This background is reinforced by the 
mandatory way of androgenic elimination through its inac-
tivation and later glucuronidation.80–84 Such an option seems 
to be the best way to assess the total androgenic activity, thus 
correlating clinical findings to the hormonal quantification.85
Although there is no consensus on the use of those sub-
stances as AFA markers, studies carried out by Carmina et 
al show a significant increase in the ADT-G level in 75% of 
normoandrogenic women with acne. In the same group, TT, 
FT, and DHEAS presented normal values. All the remain-
ing patients were treated with a COC (ethinyl estradiol [EE] 
associated to norgestimate) for 6 months, with a significant 
reduction in the levels of FT and ADT-G. The authors con-
cluded that even with the androgenic precursors at normal 
levels, ADT-G acted as an acne marker in women.38 More 
recent studies performed by Rocha et al in 2017 used liq-
uid chromatography associated to mass spectrometry. The 
authors were able to prove that women with AFA presented a 
significant increase in ADT-G level, even when T and DHEA 
were within reference values. The ADT-G level decreased 
after treatment with an oral contraceptive containing EE 
associated to drospirenone.86 Lookingbill et al’s study on 
3α-androstenediol showed a significant increase in women 
with mild to moderate acne.59 This was not confirmed by 
further studies which have detected, on the contrary, reduced 
levels of this metabolite in patients presenting the same 
clinical picture.87,88
Labrie et al analyzing cohort studies performed over 20 
years concluded that the correlation between serum T and 
androgenic clinic conditions remains undetermined. Their 
observations are related to the serum T dosage’s inability to 
reflect the androgenic hormonal conversion in the peripheral 
tissues. Sometimes, these hormones act in the tissues where 
they are generated without releasing significant amounts 
into the circulation (intracrine system). Studying the FT and 
ADT-G dosage in healthy 30- to 35-year-old women, the 
authors concluded that there is no correlation between the 
hormone and its metabolite. In their view, T dosage should be 
replaced by ADT-G through liquid chromatography associ-
ated to the mass spectrometry in order to study the androgenic 
hyperproduction or deficient cases.89
Clinical presentation
With regard to the clinical picture, the majority of studies 
agree that there are some differences in AFA compared to 
the typical presentation observed in adolescents. In adult 
women, the lesions are predominantly inflammatory, with 
mild to moderate intensity, tending to be located in the 
lower third of the face (mandibular line, perioral region, 
and side of the neck). The distribution is not yet completely 
understood.7,9,56,90–94 The predominance of comedo and mac-
rocomedo in the frontal and side regions of the face usually 
is observed in patients who are over 40 years and smokers.95 
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In a recent multicenter prospective observational study, 
the clinical characteristics of 374 patients with AFA of age 
26–66 years were assessed. A facial involvement of multiple 
regions was observed in 89.8% of cases and a small group 
representing 11.2% with acne exclusively in the mandibular 
region. This finding was contrary to the majority of previous 
studies. Interestingly, in this study, the majority of patients 
presented comedonal acne.96
Adult women with acne in their adult life have increased 
sensitivity of the skin with higher frequency of post- 
inflammatory erythema, hyper and/or hypopigmentation, and 
scarring, all of which are cosmetically disfiguring changes.10,11 
Further, in terms of physical aspects, this is undoubtedly a 
disease with a strong psychosocial impact, which can lead to 
the onset of signs and symptoms of depression and anger.97 
Quality of life (QoL) 
The term QoL can be characterized subjectively as the 
patient’s perception of the disease and treatment, while the 
technical concept comprises a series of components related 
to mental health, physical and functional ability, and the 
social dimension. Regarding dermatological diseases, stud-
ies suggest that psychometric tooling can assist the doctor 
in finding the best therapeutic proposal and to detect those 
patients psychologically affected, even when the clinical 
picture is deemed mild.98 The development of markers, instru-
ments, or questionnaires is based on evidence that there is 
a disagreement between the assessment by the doctor or the 
health professional and the patient in relation to the severity 
of the disease and the success of the treatment. Additionally, 
there are both different answers regarding the therapy and 
different satisfaction levels among patients with the same 
clinical picture.99
Studies related to acne point out a negative influence on 
QoL, including the presence of signs and symptoms of depres-
sion and anxiety, such as anger and low self-esteem.100–102
The use of disease-specific questionnaires, such as the 
QoL in acne (Acne-QoL) already translated and validated 
for the Brazilian Portuguese,103 quantifies the impact of acne 
on QoL.104,105 
Literature has demonstrated that the impact on QoL is not 
always correlated to the severity of acne. In specific cases, 
individuals present mild disease with a high impact on their 
QoL.101,106 Furthermore, there are studies proving that the 
psychological impact caused by the presence of acne seems 
to affect more female patients than male patients.11
A recent study by Rocha et al confirmed that AFA has a 
high negative impact on the patients’ QoL, even when they 
have mild to moderate acne. In the same study, the patients 
showed an improvement in QoL scores after treatment with a 
COC or even with topical medication containing azelaic acid. 
A statistical superiority was observed for the contraceptive 
group in only two Acne-QoL domains (self-perception and 
acne symptoms).107
Treatment 
Concerning the treatment for AFA, multiple options are 
available, similar to those used to treat adolescents.108 If the 
clinical picture is mild, topical retinoid, azelaic acid, and 
benzoyl peroxide are indicated as monotherapy or associated 
to topical antibiotics. The latter should not be prescribed in 
isolation, as they may induce bacterial resistance.94 As in 
monotherapy, no topical medication is able to treat all the 
etiopathogenic aspects of acne; frequently, it is required to 
associate topical medications or topics added to systemic 
drugs.108
Oral antibiotics, mainly those that derivate from cyclins, 
help more inflammatory forms, but they have a high relapse 
rate after they are stopped.109 Oral isotretinoin is also used, 
but it can fail in keeping adult patients free of lesions after 
months. There is a higher incidence of irritating symptoms 
due to an increased mucocutaneous sensibility found in this 
age group.110,111 
A study carried out by Rademaker et al on the use of a 
low-dose oral isotretinoin (5 mg a day) to treat mild intensity 
acne in adults for 32 weeks showed therapeutic success, 
improvement in QoL, and minimal side effects. Regarding 
relapse rates, the authors followed part of the group and in 
2017 published the results, disclosing an absence of relapse of 
40%. Among the relapse group (60%), about 50% of patients, 
after 7 months without treatment, preferred to restart isotreti-
noin even in doses as low as 5–10 mg, twice a week.112,113
Hormonal treatments, mainly those with an association 
of estrogens and new antiandrogenic progestins (compounds 
present in certain contraceptives), can be used by women with 
no formal contraindications when they also want contracep-
tion.114 These drugs promote a reduction in FT levels through 
an increase of SBHG, a reduction of gonadotropin release, a 
decrease of ovarian production, and an antiandrogenic effect 
on sebaceous gland receptors.115–118
COCs are drugs combining an estrogen, usually EE, to 
synthetic progestins. These medications have undergone 
several evolutions since their development. One of them is 
related to the amount of estrogen. Initially, 100 µg per tablet 
presented a large incidence of severe side effects, such as deep 
vein thrombosis, cerebrovascular accident, and myocardial 
 
Cl
in
ica
l, 
Co
sm
et
ic 
an
d 
In
ve
st
ig
at
io
na
l D
er
m
at
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
0.
14
4.
94
.9
 o
n 
06
-A
pr
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical, Cosmetic and Investigational Dermatology 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
65
Adult-onset acne: prevalence, impact, and management challenges
infarction.119 Presently, with doses between 20 and 35 µg, 
they are very safe.120
Another important evolution is related to the progestin 
contained in the COCs. There are several progestin genera-
tions; the most recent are less androgenic, such as norges-
timate and desogestrel,121 or they present an antiandrogenic 
effect, such as drospirenone.122
A recent review by the Cochrane Library analyzed 31 
comparative studies among contraceptives used to treat acne. 
The conclusion was that the COCs were more effective than 
the placebo, with cyproterone acetate and chlormadinone pre-
senting better results than levonorgestrel, and drospirenone 
better than norgestimate.123 Favorable estrogen effects can 
be eliminated by the inclusion of the androgenic progestin, 
especially the derivate from 19-nortestosterone.124
The more frequent side effects are nausea, headache, 
breast pain, sporadic bleeding, and decreased libido. The 
incidence is quite different, depending on the combination 
of each contraceptive.125 
It must be pointed out that the use of COCs offers several 
benefits to women in addition to the improvement of acne, 
such as the reduction of dysmenorrhea as well as protection 
against ovary and endometrium cancer, anemia caused by 
iron deficiency, and pelvic inflammatory disease.125 
In relation to venous thromboembolism, its incidence 
in young women is low, and there is a small increase in the 
risk, 0.05%–0.1%, for COC users.126 It must be pointed out 
that the risk for thromboembolism in the postpartum period 
is 0.5%; during pregnancy, it is 0.1%.127
The introduction of COC must be performed after careful 
anamnesis, and it is contraindicated for women with a high 
risk of deep venous thrombosis and cardiovascular diseases, 
such as family history and/or smoking habit.125
Spironolactone is an aldosterone antagonist, used since 
1957, that has antiandrogenic properties.128 It acts by blocking 
5α-reductase activity and the androgen receptor in peripheral 
tissues.129,130 A study published by Sato et al shows the effec-
tiveness of spironolactone to treat acne in Asian women, with 
a 47% good response using an initial dose of 200 mg per day, 
then reducing the dose every 4 weeks. In monotherapy, 80% 
of patients presented menstrual  irregularity.131 Spironolac-
tone’s side effects are dose-dependent, and the most frequent 
are increase of diuresis, headache, dizziness, menstrual 
irregularity, breast pain, fatigue, and hyperpotassemia.132 
A recent retrospective study found that in young women, 
who did not have kidney disease and were nonusers of other 
medications that might increase potassium levels, a periodic 
monitoring of these levels is not required.133
Although the drug is associated with tumors in animals 
when the doses were much higher than those prescribed in 
clinical practice, human studies with a duration of >5 years 
of use did not verify a carcinogenic effect.134,135
The drug can be used to promote androgenic blockade in 
patients using an intrauterine device with levonorgestrel or to 
increase the androgenic blockade in patients using COCs.130 
In these cases, 100 mg per day is safe and rarely associated 
with side effects.136
A systematic review published in 2017 concluded that 
the evidence for its use to treat acne in adult women is still 
poor, and a recommendation is still based on the opinion 
of experts or consensuses. Randomized, double-blind, and 
controlled studies are required to assess its effectiveness.137
Conclusion
The fact that acne is a self-limiting disease for most patients 
is not the case for the group of women who present this 
condition in adult life. Genetic factors that command an 
excessive activation of the immune system, especially the 
innate system, seem to justify the persistence of the lesions.
There are clinical characteristics that seem to differentiate 
the disease in adult life; among them are the predominance 
of inflammatory lesions, premenstrual worsening, and the 
lesions distribution on the face. Curiously, although often less 
intense in adulthood, the negative impact on QoL is greater 
than in adolescence.
Although there are options for its treatment, in highlight 
to the hormonal treatment, there are still specific medica-
tions for this age group that can be directed to the possible 
mechanisms implicated in its chronicity.
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